Click here for slides on this topic


Albumin

The major protein component of blood and many animal tissues.


The following content matched the glossary term: Albumin

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study

Top

Seaquist ER, Miller ME, Bonds DE for the ACCORD Investigators. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care. 2012 35(2) 409 414.  Seaquist and colleagues examined data from an Action to Control Cardiovascular Risk in Diabetes (ACCORD) substudy to explore the relationship between frequent and unrecognized hypoglycemia and mortality.

Nontraditional markers of glycemia: associations with microvascular conditions(2)

Top

Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, Steffes MW. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 2011;34(4):960-7. To compare the associations of nontraditional (fructosamine, glycated albumin, 1,5-anhydroglucitol [1,5-AG]) and standard (fasting glucose, HbA(1c)) glycemic markers with common microvascular conditions associated with diabetes mellitus.

Nontraditional markers of glycemia: associations with microvascular conditions

Top

Nontraditional markers of glycemia associations with microvascular conditionsSelvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, Steffes MW.Diabetes Care. 2011 Feb 18. Epub ahead of print   To compare the associations of nontraditional (fructosamine, glycated albumin, 1,5-anhydroglucitol [1,5-AG]) and standard (fasting glucose, glycated HbA(1c)) glycemic markers with common microvascular conditions associated with diabetes mellitus.

Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus

Top

Ai M, Otokozawa S, Schaefer EJ, et al. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clin Chimica Acta.. 2009;406(1-2):71-74. Diabetes mellitus is a major risk factor for coronary heart disease (CHD), renal failure, retinopathy, and neuropathy. Lowering glycosylated hemoglobin (HbA1c) as well as low-density lipoprotein-cholesterol (LDL-C) has been associated with a decreased risk of these complications.

Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus

Top

Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 2009;103(10):1364-1367. It is important identify patients with very high cardiovascular risk to intensify their therapy. Our aim was to assess the association between retinopathy and incident cardiovascular events (cardiovascular disease [CVD]) in patients with type 2 diabetes mellitus (DM).

Risk of type 2 diabetes among individuals with high and low glomerular filtration rates

Top

Lorenzo C, Nath SD, Hanley AJ, Abboud HE, Gelfond JA, Haffner SM. Risk of type 2 diabetes among individuals with high and low glomerular filtration rates. Diabetologia. 2009;52(7):1290-1297. Metabolic abnormalities frequently develop prior to the diagnosis of type 2 diabetes and chronic kidney disease. However, it is not known whether GFR predicts the onset of type 2 diabetes.

C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study

Top

Bruno G, Fornengo P, Novelli G, et al. C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes. 2009;58(4):926-933. OBJECTIVE: To determine to what extent plasma C-reactive protein (CRP) values influence 5-year all-cause and cardiovascular mortality in type 2 diabetic individuals, independently of albumin excretion rate (AER) and other cardiovascular risk factors, and its incremental usefulness for predicting individual risk of mortality.

1 2 3 4 Next 

Slide Library Results

Search Results for: Albumin Slides Found: 22
Microvascular Complications in Hispanics and Non-Hispanic Whites
Microalbuminuria Predicts CV Risk at Levels Below Current Definition
IRMA 2: Renoprotectie Effects of Irbesartan in Type 2 Diabetes
CALM: Renoprotection With Candesartan vs Lisinopril in Type 2 Diabetes
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
Type 2 Diabetes Treatment Intensification Albuminuria | NDEI
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Treatment | NDEI
IDF Type 2 Diabetes Guidelines Kidney Disease | NDEI
IDF Guidelines Type 2 Diabetes Diagnosis Older Adults Elderly | NDEI
BP Treatment Goal for Adults With CKD JNC 8 Guidelines PPT | NDEI
Therapy Initiation & Goals for Blood Pressure | NDEI
Diabetes Pregnancy Guidelines Renal Nephropathy | NDEI
Edinburgh Type 2 Diabetes Study Severe Hypoglycemia Slide PPT | NDEI
AACE 2015 Diabetes Guidelines Nephropathy Management Microvascular | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
Kidney Disease in Type 2 Diabetes for CVD Prevention PPT | NDEI
ADA Guidelines Treating Microvascular Complications in Children With Type 1 Diabetes | NDEI
ASCVD Risk Assessment Algorithm NLA Cholesterol Guidelines | CCMD